8-K: HeartSciences Inc. COO Mark Hilz Passes Away

HeartSciences Inc. announced the passing of its Chief Operating Officer, Mark Hilz, on April 1, 2026, with no immediate plans to replace the role.

Summary

• HeartSciences Inc. reported the death of its Chief Operating Officer, Corporate Secretary, and Board Member, Mark Hilz, on April 1, 2026, at the age of 67.
• Mr. Hilz had been a Board Member since 2013 and served as COO and Corporate Secretary since March 2022.
• The company does not plan to hire a new COO or replace his role in the near future, citing the launch of the MyoVista Insights software platform and the FDA submission for the MyoVista wavECG device.
• The company anticipates no changes to its business, operations, or commercialization plans as a result of his passing.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event; while the passing of a key executive is a negative, the company's proactive communication about no anticipated business impact mitigates immediate concern.

Positives

• The company has launched its MyoVista Insights software platform.
• The MyoVista wavECG device has been submitted to the FDA for 510(k) premarket clearance.
• The company does not anticipate any disruption to its business, operations, or commercialization plans due to the COO's passing.

Negatives

• The unexpected passing of a key executive, Mark Hilz (COO, Corporate Secretary, Board Member).

Risks

• Potential impact on company morale and operational continuity due to the loss of a key executive.
• Reliance on the successful FDA clearance of the MyoVista wavECG device for commercialization.

Future Outlook

The company does not anticipate any changes to its business, operations, or planned commercialization of the MyoVista Insights platform, including its MyoVista wavECG device submission to the FDA, as a result of Mr. Hilz's passing.

Management Comments

• The Company mourns the loss of Mr. Hilz, an esteemed colleague, visionary and friend, and extends its sincere condolences to his family and loved ones.

Industry Context

StockSavvy.ai notes that the loss of a key executive, particularly a COO, can create uncertainty, but HeartSciences Inc.'s stated confidence in maintaining operations and commercialization plans, especially with product launches and FDA submissions underway, suggests a degree of operational resilience.

Management Changes

Stakeholder Impact

• Shareholders: Potential short-term uncertainty due to the loss of a key executive, but mitigated by company statements on operational continuity.
• Employees: Potential impact on morale, but company is communicating a stable operational outlook.
• Board of Directors: Need to address the vacancy in the COO and Corporate Secretary roles and potentially on the board, though no immediate replacement is planned.

Next Steps

• Continue commercialization of the MyoVista Insights platform.
• Await FDA clearance for the MyoVista wavECG device.

Key Dates

Keywords

HeartSciences Inc., Mark Hilz, COO, Corporate Secretary, Board of Directors, MyoVista Insights, wavECG, FDA clearance